Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$16.07-13.4%$8.61$4.92▼$28.60$10.15M1.34172,929 shs279,795 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-13.37%+1.07%+123.35%+176.12%+101.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.615 of 5 stars3.83.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.60Strong Buy$25.0055.57% UpsideCurrent Analyst Ratings BreakdownLatest LBOW, ARTL, IPU, and IVPU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.006/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.004/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)Latest LBOW, ARTL, IPU, and IVPU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ARTLArtelo Biosciences-$0.13N/AN/AN/AN/AN/A5/13/2025Q1 2025ARTLArtelo Biosciences-$0.78-$4.32-$3.54-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.490.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5550,000542,000Not OptionableLBOW, ARTL, IPU, and IVPU HeadlinesRecent News About These CompaniesArtelo Biosciences completes reverse stock split and reports ...July 13 at 8:38 PM | investing.comArtelo Biosciences Presents Preclinical Data on ART26.12 as ... - NasdaqJuly 11, 2025 | nasdaq.comARTL - Artelo Biosciences Inc Financials | MorningstarJuly 11, 2025 | morningstar.comMArtelo Biosciences (NASDAQ:ARTL) Upgraded at D Boral CapitalJuly 11, 2025 | americanbankingnews.comArtelo Biosciences stock soars after positive preclinical pain dataJuly 10, 2025 | investing.comArtelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical StudyJuly 10, 2025 | msn.comArtelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society SymposiumJuly 9, 2025 | globenewswire.comArtelo Biosciences (NASDAQ:ARTL) Rating Increased to Buy at D. Boral CapitalJuly 9, 2025 | americanbankingnews.comArtelo Biosciences, Inc. Common Stock (ARTL) - NasdaqJuly 8, 2025 | nasdaq.comD. Boral Capital Upgrades Artelo Biosciences (ARTL)July 8, 2025 | msn.comArtelo Biosciences Stock Climbs on Positive Preclinical Efficacy for Depression Drug CandidateJuly 8, 2025 | marketwatch.comArtelo Biosciences Stock Soars 114% After Promising Depression Treatment DataJuly 8, 2025 | msn.comArtelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression DrugJuly 8, 2025 | msn.comArtelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression ModelJuly 7, 2025 | globenewswire.comARTL - Artelo Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMArtelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain - Seeking AlphaJuly 2, 2025 | seekingalpha.comArtelo Biosciences Inc. (ARTL) Stock Price Today - WSJJune 30, 2025 | wsj.comArtelo Biosciences Stock Rises on Positive Trial Data for Treatment for Persistent PainJune 30, 2025 | marketwatch.comArtelo Biosciences stock soars after positive first-in-human study resultsJune 30, 2025 | za.investing.comArtelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment TrialJune 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLBOW, ARTL, IPU, and IVPU Company DescriptionsArtelo Biosciences NASDAQ:ARTL$16.07 -2.48 (-13.37%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$16.12 +0.05 (+0.34%) As of 07/15/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
